MiniMed Reports Strong Q1 Results but Faces Cash Flow Challenges
On September 1, 2026, MiniMed Group (NASDAQ:MMED) reported first-quarter fiscal 2027 results showing strong revenue growth. Worldwide net sales increased by 16.6% to $843 million with U.S. sales up 13.1%. The company raised its full-year organic revenue guidance from approximately 10% to 10.5%, driven in part by new product launches and a robust pipeline. Nine analysts revised their price targets upward, citing strong performance metrics such as over 20% year-over-year growth in U.S. pump sales and increased adoption of its continuous glucose monitoring (CGM) systems. However, the company's cash flow remains under pressure due to separation costs from becoming an independent entity post-Medtronic spin-off. Despite a reported free cash outflow of $90 million for the quarter—largely attributed to one-time expenses related to transitioning services and product development—the underlying business showed positive momentum. Analysts remain optimistic about MiniMed's long-term growth potential, though concerns persist regarding its near-term financial health.
Topics: analyst upgrades diabetes tech medical devices revenue growth